Lazard Capital raised its price target for Vanda Pharmaceuticals shares citing positive feedback on the company's sleep disorder drug tasimelteon. The firm keeps a Buy rating on the stock.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?